The Middle EAST Leukapheresis Product Market was valued at USD 0.45 billion in 2024 and is projected to reach USD 1.20 billion by 2034, registering a CAGR of 10.0%. This growth trajectory is underpinned by several factors, including the increasing prevalence of hematological disorders, advancements in leukapheresis technology, and a rising demand for blood and blood component therapies. The...